Hormonal Male Contraception: A Real Chance?

  • Eberhard Nieschlag
  • Hermann M. Behre
  • Gerhard F. Weinbauer
Part of the Schering Foundation Workshop book series (SCHERING FOUND, volume 4)


Health and prosperity of individuals and communities alike are linked to population growth. European and North American countries are now in the late phase of a demographic transition and have achieved largely stable populations where birth rates equal or only slightly exceed death rates. This balance depends to a paramount extent on the availability of methods for birth control. This is illustrated by representative opinion polls performed in Germany 1958 and in 1989 (Allensbach 1958 and 1989). At both time points the ideal family size, in the opinion of the majority of couples of reproductive age, comprised two children.


GnRH Agonist Male Fertility GnRH Antagonist Cyproterone Acetate Testosterone Enanthate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aitken RJ, Paterson M, Thillai Koothan P (1992) Risks and benefits of immunological contraception. In: Nieschlag E, Habenicht OF (eds) Spermatogenesis — fertilization — contraception: Molecular, cellular and endocrine events in male reproduction. Springer Verlag, HeidelbergGoogle Scholar
  2. Akhtar FB, Marshall GR, Wickings E, Nieschlag E (1983) Reversible induction of azoospermia in rhesus monkeys by constant infusion of a GnRH agonist using osmotic minipumps. J Clin Endocrinol Metab 56: 534 – 540PubMedCrossRefGoogle Scholar
  3. Allensbach Umfragen No. 1020 (1958) and No. 5053 (1989)Google Scholar
  4. Alvarez-Sanchez F, Faundes A, Brache V, Leon P (1977) Attainment and maintenance of azoospermia with combined monthly injections of depot medroxyprogesterone acetate and testosterone enanthate. Contraception 15: 635 – 648PubMedCrossRefGoogle Scholar
  5. Bardin CW, Swerdloff RS, Santen RI (1991) Androgens: risks and benefits. J Clin Endocrinol Metab 73: 4 – 7PubMedCrossRefGoogle Scholar
  6. Behre HM, Oberpenning F, Nieschlag E (1990) Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In: Nieschlag E, Behre HM (eds) Testosterone — Action, deficiency, substitution. Springer Verlag, Heidelberg pp 115–135CrossRefGoogle Scholar
  7. Behre HM, Klein B, Steinmeyer E, Nieschlag E (1992a) Effective suppression of luteinizing hormone and testosterone by single doses of the new GnRH antagonist cetrorelix (SB-75) in normal men. J Clin Endocr Metab (in press)Google Scholar
  8. Behre HM, Nashan D, Hubert W, Nieschlag E (1992b) Depot gonadotropinreleasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74: 84–90PubMedCrossRefGoogle Scholar
  9. Behre HM, Nieschlag E (1992c) Testosterone buciclate (20-Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamies of the new long-acting androgen ester. J Clin Endocrinol Metab (in press)Google Scholar
  10. Bergquist C, Nillius SG, Bergh T, Skering G, Wide G (1979) Inhibitory effects on gonadotropin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol 91: 610–618Google Scholar
  11. Bhasin S, Heber D, Steiner BS, Handelsmann DJ, Swerdloff RS (1985) Hormonal effects of gonadotropin-releasing-hormone (GnRH) agonist in the human male. III. Effects of long-term combined treatment with GnRH agonist and androgen. J Clin Endocrinol Metab 60: 998-1003Google Scholar
  12. Bhasin S, Yuan QX, Steiner BS, Swerdloff RS (1987) Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in men. Effects of longterm treatment with GnRH agonist infusion and androgens. J Clin Endocrinol Metab 65: 568-574Google Scholar
  13. Bhasin S, Swerdloff RS, Steiner B et al. (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 74: 75 – 83PubMedCrossRefGoogle Scholar
  14. Bouchard P, Garcia E (1987) Influence of testosterone substitution on sperm suppression by LHRH agonists. Horm Res 28: 175 – 180PubMedCrossRefGoogle Scholar
  15. Bremner WJ, Bagatell CJ, Steiner RA (1991) Goandotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive. J Clin Endocrinol Metab 73: 465 – 469PubMedCrossRefGoogle Scholar
  16. Burris AS, Ewing LL, Sherins RJ (1988) Initial trial of slow release testosterone microspheres in hypogonadal men. Fertil Steril 50: 493 – 497PubMedGoogle Scholar
  17. Clayton RN, Channabasavaiah K, Stewart JM, Catt KJ (1982) Hypothalamic regulation of pituitary gonadotropin-releasing hormone receptors: effects of hypothalamic lesions and a gonadotropin-releasing hormone antagonist. Endocrinology 110: 1108 – 1115PubMedCrossRefGoogle Scholar
  18. Cooper TG (1992) The epididymis as a site of contraceptive attack. In: Nieschlag E, Habenicht OF (eds) Spermatogenesis — fertilization — contraception: Molecular, cellular and endocrine events in male reproduction. Springer Verlag, HeidelbergGoogle Scholar
  19. Delanoe D, Fougevrollas B, Meyer L, Thonneau P (1984) Androgenisation of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1: 276PubMedCrossRefGoogle Scholar
  20. Diczfalusy E (1987) Has family planning a future? In: Diczfalusy E, Bydgemann M (eds) Fertility regulation today and tomorrow. Raven Press, New York pp 3 – 9Google Scholar
  21. Doelle GC, Alexander AN, Evans RM, Linde R, Rivier J, Vale W, Rabin D (1983) Combined treatment with an LHRH agonist and testosterone in man. J Androl 4: 298 – 302PubMedGoogle Scholar
  22. Fogh M, Corcker CS, Hunter WM, McLean H, Philip J, Schon G, Skakkebaek NE (1979) The effects of low doses of cyproterone acetate on some functions of the reproductive system in normal men. Acta Endocrinol 91: 545PubMedGoogle Scholar
  23. Frick J, Aulitzky W (1986) Effects of a potent LHRH agonist on the pituitary-go- nadal axis with and without testosterone substitution. Urol Res 14: 261 – 264PubMedCrossRefGoogle Scholar
  24. Friedl KE, Hannan CJ, Jones RE, Plymate SR (1990) High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Mebatolism 39: 69 – 74Google Scholar
  25. Gaitan D, Lindner J, Farley MG, Monroe SE, Pavlou SN (1991) Antireproductive properties of a novel GnRH antagonist in men. 73rd Ann Meeting Endocr Soc, Washington, abstr 1156Google Scholar
  26. Giwercman A, Skakkebaek NE (1986) The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review. Int J Androl 9: 28-52Google Scholar
  27. Gooren LJG, Polderman KH (1990) Safety aspects of androgen therapy. In: Nieschlag E, Behre HM (eds) Testosterone–Action, deficiency, substitution. Springer Verlag, Heidelberg, pp 182 – 203CrossRefGoogle Scholar
  28. Hamilton DW, Waites GMH (eds) (1990) Cellular and molecular events in spermiogenesis. Cambridge University PressGoogle Scholar
  29. Handelsman, DJ, Conway AJ, Boylan LM (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J. Clin Endocrinol Metab 71: 216 – 222PubMedCrossRefGoogle Scholar
  30. Heber D, Dodson R, Swerdloff RS, Channabasavaiah K, Stewart JM (1982) Pituitary receptor site blockade by a gonadotropin-releasing hormone antagonist in vivo: mechanism of action. Science 216: 420 – 421PubMedCrossRefGoogle Scholar
  31. Hedman M, Gottlieb C, Svanborg K, Bydgeman M, de la Torre B (1988) Endocrine, seminal and peripheral effects of depot medroxyprogesterone acetate and testosterone enanthate in men. Int J Androl 11: 265 – 276PubMedCrossRefGoogle Scholar
  32. Karten MI, Hoeger CA, Hook WA, Lindberg MC, Naqvi RH (1990) The development of safer GnRH antagonists: strategy and status. In: Bouchard P, Haour F, Franchimont P, Schatz B (eds) Recent progress on GnRH and gonadal peptides, Elsevier, Paris, pp 147 – 158Google Scholar
  33. Knuth UA, Behre HM, Belkien L, Bents H, Nieschlag E (1985) Clinical trial of 19-nortestosterone of male fertility regulation. Fertil Steril 44: 814 – 821PubMedGoogle Scholar
  34. Knuth UA, Maniera H, Nieschlag E (1989a) Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 52: 1041 – 1047Google Scholar
  35. Knuth UA, Yeung CH, Nieschlag E (1989b) Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyproges-terone-acetate ( Clinovir) for male contraception. Fertil Steril 51: 10111018Google Scholar
  36. König U (1991) Revolution bei der Verhütung: Jetzt sind die Manner dran. Stern 24/91: 28 – 34Google Scholar
  37. Leonard JM, Paulsen CA (1978) The use of androgens plus synthetic steroids as a reversible means of regulating male fertility. In: Fabbrini A, Steinberger E (eds) Recent progress in andrology. Academic Press, New York p 271Google Scholar
  38. Linde R, Doelle GC, Alexander N, Kirchner F, Vale W, Rivier J, Rabin D (1981) Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men. N Engl J Med 305: 663–667PubMedCrossRefGoogle Scholar
  39. Marshall GR, Akhtar FB, Weinbauer GF, Nieschlag E (1986) Gonadotrophinreleasing hormone ( GnRH) overcomes GnRH antagonist-induced suppression of LH secretion in primates. J Endocrinol 110: 145–150Google Scholar
  40. Meyer WJ, Walker PA, Emory LE, Smith ER (1985) Physical, metabolic and hormonal effects on men of long-term therapy with medroxyprogesterone acetate. Fertil Steril 43: 102 – 109PubMedGoogle Scholar
  41. Michel E, Bents H, Akthar FB, Honig! W, Knuth UA, Sandow J, Nieschlag E (1985) Failure of high-dose sustained-release luteinizing hormone agonist (buserelin) plus oral testosterone to suppress male fertility. Clin Endocrinol 23: 663–675CrossRefGoogle Scholar
  42. Moeloek N (1990) Combination of testosterone enanthate + DMPA and 19nortestosterone-hexyloxyphenylpropionate + DMPA for male contraception (abstract). 16th Conference on Science and Technology of ThailandGoogle Scholar
  43. Moltz L, Römmler A, Post K, Schwartz U, Hammerstein J (1980) Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in man. Contraception 21: 393PubMedCrossRefGoogle Scholar
  44. Moudgal NR, Ravindranath N, Murthy GS, Dighe RR, Aravindan GR (1991) On the development of a male contraceptive vaccine. In: Moudgal NR, Yoshinaga K, Rao AJ, Adiga RR (eds) Perspectives in primate reproductive biology. Wiley Eastern, New Dehli, pp 297 – 306Google Scholar
  45. Nieschlag E (1986) Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Sciarra JJ, Spieler J (eds) Male contraception: advances and future prospects. Harper and Row, Philadelphia, pp 395–400Google Scholar
  46. Nieschlag E (1987) Vasektomie–pro und contra. Dtsch Med Wochenschr 112: 1107–1109PubMedCrossRefGoogle Scholar
  47. Nieschlag E, Behre HM (1990) Pharmacology and clinical use of testosterone. In: Nieschlag E, Behre HM (eds.) Testosterone–Action, deficiency, substitution. Springer Verlag, Heidelberg, pp 92–114CrossRefGoogle Scholar
  48. Nieschlag E, Hoogen H, Bölk M, Schuster H, Wickings EJ (1978) Clinical trial with testosterone undecanoate for male fertility control. Contraception 18: 607–614PubMedCrossRefGoogle Scholar
  49. Nieschlag E, Waites GMH, Paulsen CA, Handelsman DJ (1990) Safety of testosterone enanthate/Tumorigenic effect of testosterone ( Letter to the Editor ). Lancet 336: 1517-1518Google Scholar
  50. Pangkahila W (1991) Reversible azoospermia induced by an androgen-proges- tin combination regimen in Indonesian men. Int J Androl 44: 248–256CrossRefGoogle Scholar
  51. Patanelli DJ (ed) (1978) Hormonal control of male fertility. Bethesda US Department of Health, Education and Welfare. National Institutes of Health. Publication no. (NIH) 78: 1097Google Scholar
  52. Paulsen CA, Bremner WJ, Leonard JM (1982) Male contraception: Clinical trials. In: Mishell DR (ed) Advances in fertility research. Raven Press, New York, pp 157–170Google Scholar
  53. Pavlou SN, Debold CR, Island DP, Wakefield G, Rivier J, Vale W, Rabin D (1986) Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men. J Clin Endocrinol Metab 63: 303–308PubMedCrossRefGoogle Scholar
  54. Pavlou SN, Brewer K, Farley MG, Lindner, J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn M, Herbert CM (1991) Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73: 1360–1369PubMedCrossRefGoogle Scholar
  55. Quian SZ (1987) Tripterygidium wilfordii, a new lead in male fertility regulation. In: Diczfalusy E, Bydgeman M (eds) Fertility regulation today and tomorrow. Raven Press, New York pp 217–232Google Scholar
  56. Rabin D, Evans RM, Alexander AN, Doelle GC, Rivier J, Vale W, Liddle G (1984) Heterogeneity of sperm density profiles following 20-week therapy with high-dose LHRH analog plus testosterone. J Androl 5: 176–180PubMedGoogle Scholar
  57. Schearer SB, Alvarze-Sanchez F, Anselmo G, Brenner P, Coutinho E, LathenFaundes A, Frick J, Heinild B, Johansson EDB (1978) Hormonal contraception for men. Int J Androl Suppl 2: 680–712CrossRefGoogle Scholar
  58. Schröder FF (1990) Androgens and carcinoma of the prostate. In: Nieschlag E, Behre HM (eds) Testosterone–Action, deficiency, substitution. Springer Verlag, Heidelberg, pp 245–260CrossRefGoogle Scholar
  59. Schürmeyer Th, Knuth UA, Belkien L, Nieschlag E (1984a) Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet 1: 417420Google Scholar
  60. Schürmeyer Th, Knuth UA, Freischem CW, Sandow J, Akthar FB, Nieschlag E (1984b) Suppression of pituitary and testicular function in normal men by constant gonadotropin-releasing hormone agonist infusion. J Clin Endocrinol Metab 59: 1–6CrossRefGoogle Scholar
  61. Segal S (ed) (1985) Gossypol–a potential contraceptive for men. Plenum Press, New YorkGoogle Scholar
  62. Soufir JC, Jouannet P, Marson J, Soumah A (1983) Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment. Acta Endocrinol 102: 625PubMedGoogle Scholar
  63. Srinath BR, Wickings EJ, Nieschlag E (1983) Active immunization with follicle-stimulating hormone for fertility control: a 4 1/2 year study in male rhesus monkeys. Fertil Steril40: 110–117Google Scholar
  64. Tom L, Salameh W, Bhasin S, Steiner B, Peterson M, Swerdloff RS (1991) Male contraception: Achievement of reversible azoospermia by combined gonadotropin releasing hormone antagonist and testosterone treatment. 73rd Ann Meeting Endocr Soc, Washington, abstr 1154Google Scholar
  65. Turner JW, Kirkpatrick JF (1982) Androgens, behaviour and fertility control in feral stallions. J Reprod Fertil 32: 79Google Scholar
  66. Wallace EM, Wu FCW (1990) Effect of depot medroxyprogesterone acetate and testosterone enanthate on serum lipoproteins in man Contraception 41: 63–71Google Scholar
  67. Wang C, Yeung KK (1980) Use of a low dosage oral cyproterone acetate as a male contraceptive. Contraception 21: 245PubMedCrossRefGoogle Scholar
  68. Weinbauer GF, Nieschlag E (1985) Regulation of primate testicular function by GnRH analogues. Med Biol 63: 210–217Google Scholar
  69. Weinbauer GF, Nieschlag E (1990) The role of testosterone in spermatogenesis. In: Nieschlag E, Behre HM (eds) Testosterone–Action, deficiency, substitution. Springer Verlag, Heidelberg pp 23–50CrossRefGoogle Scholar
  70. Weinbauer GF, Nieschlag E (1992) Peptide and steroid regulation of spermatogenesis in primates. In: Robaire, B. (ed) The male germ cell: spermatogonium to fertilization. New York Academy of Sciences Annals vol 637, pp 107–121Google Scholar
  71. Weinbauer GF, Marshall GR, Nieschlag E (1986) New injectable testosterone ester maintains serum testosterone of castrated monkeys in the normal range for four months. Acta Endocrinol 113: 128–132PubMedGoogle Scholar
  72. Weinbauer GF, Respondek M, Themann H, Nieschlag E (1987) Reversibility of long-term effects of GnRH agonist administration on testicular histology and sperm production in the nonhuman primate. J Androl 8: 319–329PubMedGoogle Scholar
  73. Weinbauer GF, Göckeler E, Nieschlag E (1988) Testosterone prevents complete suppression of spermatogenesis in the gonadotropin-releasing hormone (GnRH) antagonist-treated non-human primate ( Macaca fascicularis ). J Clin Endocrinol Metab 67: 284-290Google Scholar
  74. Weinbauer GF, Khurshid S, Fingscheidt U, Nieschlag E (1989) Sustained inhibition of sperm production and inhibin secretion induced by a gonadotrophin-releasing hormone antagonist and delayed testosterone substitution in non-human primates ( Macacaa fascicularis ). J Endocrinol 123: 303-310Google Scholar
  75. Weinbauer GF, Behre HM, Nieschlag E (1990) Contraceptive studies with GnRH analogs in men and non-human primates. In: Bouchard P, Haour F, Franchimont P, Schatz B (eds) Recent progress on GnRH and gonadal peptides, Elsevier, Paris, pp 181–194Google Scholar
  76. Weinbauer GF, Behre HM, Fingscheidt U, Nieschlag E (1991) Human follicle-stimulating hormone exerts a stimulatory effect on spermatogenesis, testicular size, and serum inhibin levels in the gonadotropin-releasing hormone antagonist-treated nonhuman primate ( Macaca fascicularis ). Endocrinology 129: 1831-1839Google Scholar
  77. WHO (1972-1983) Special Programme of Research Development and Research Training in Human Reproduction: Annual Reports. GenevaGoogle Scholar
  78. WHO Task Force on Methods for the Regulation of Male Fertility (1990) Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336: 955–959CrossRefGoogle Scholar
  79. WHO (1991) Special Programme of Research, Development and Research Training in Human Reproduction. Annual Technical Report 1990. Geneva pp 74–75Google Scholar
  80. Wu FCW, Aitken RJ (1989) Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril 51: 691–698PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • Eberhard Nieschlag
  • Hermann M. Behre
  • Gerhard F. Weinbauer

There are no affiliations available

Personalised recommendations